Amarin Corporation PLC (AMRN)

4.860
+0.420(+9.46%)
After Hours
4.860
0.000(0.00%)
- Real-time Data
  • Volume:
    9,970,071
  • Bid/Ask:
    4.810/4.860
  • Day's Range:
    4.495 - 5.005

AMRN Comments

What is your sentiment on Amarin Corporation PLC?
or
Market is currently closed. Voting is open during market hours.

All Comments

(162)
  • EU approval, nice
    1
    • Holding April 30 6.50 strike call options for EU approval!
      0
      • over 20 Dollar end of this year
        0
        • $8 this week
          0
          • https://www.investing.com/news/leerink-partners-stick-to-their-buy-rating-for-amarin-corporation-plc-2436922
            0
            • What Does champ mean
              0
              • https://investor.amarincorp.com/news-releases/news-release-details/amarin-receives-positive-chmp-opinion-icosapent-ethyl
                0
                • Amarin Corporation plc (NASDAQ: AMRN) announced that the Chinese Society of Cardiology has included icosapent ethyl in its updated ‘Guidelines for Primary Prevention of Cardiovascular Diseases for 2021'
                  0
                  • $8 By Feb. 2021
                    0
                    • nice call...where next?
                      0
                    • nice call...where next?
                      0
                  • https://www.globenewswire.com/news-release/2021/01/07/2154744/0/en/Amarin-Provides-Preliminary-2020-Results-and-2021-Outlook.html this is going to be a pleasant summer I would say
                    0
                    • Yeaaah, a very slight wobble ..  great u r   ;-P
                      0
                      • Had a slight wobble, I think still likely to be heading upwards.
                        0
                        • What happen with this stock? Maybe stock split?
                          0
                          • Stock fell down go boom.
                            0
                        • https://investor.amarincorp.com/news-releases/news-release-details/amarin-shares-topline-data-partners-pivotal-phase-3-study
                          0
                          • Mr. Xin Ni: "VASCEPA has huge commercial potential in the fast-growing Chinese market. We will work with Amarin to submit the new drug application as soon as possible to bring this cross-era innovative drug to China.”
                            0
                          • There were approximately 180.4 million hypertriglyceridemia (HTG) patients in China in 2019, representing approximately 20.2% of the adult population
                            0
                        • I told you to switch with TEVA
                          0
                          • lol $5.57
                            0
                          • going to $20 again !??  I'm scared, very
                            0
                        • what's causing stock to go down
                          0
                          • hopefully stock goes up been beaten up for awhile now
                            0
                            • It should go back at least above 7 because Vascepa generics did not lead to a decrease in sales, rather ... an increase? like if customers just want the most technological
                              0
                            • ... or that the demand is much higher than the supply
                              0
                            • agreed!
                              0
                          • My congratulations to Amarin for beating all earnings expectations in its third quarter
                            0
                            • More important than the one below :  --> VASCEPA® (ICOSAPENT ETHYL) FOUND TO SIGNIFICANTLY REDUCE CARDIOVASCULAR EVENTS IN PATIENTS WITH COMPROMISED RENAL FUNCTION AT BASELINE IN PRESPECIFIED AND POST HOC SUBGROUP ANALYSES OF LANDMARK REDUCE-IT® STUDY
                              0
                              • http://investor.amarincorp.com/news-releases/news-release-details/vascepar-icosapent-ethyl-found-significantly-reduce-ischemic
                                1
                                • This is meaningful:   https://www.globenewswire.com/news-release/2020/10/05/2103391/0/en/Latest-Research-Evaluating-VASCEPA-Icosapent-Ethyl-Mechanisms-of-Action-Presented-at-European-Atherosclerosis-Society-EAS-Congress-2020.html     OTOH  VASCEPA is the original and genuine oil, not just a generic from small companies  is it ok!?
                                  1
                                  • This result is meaningful:  https://www.globenewswire.com/news-release/2020/10/05/2103391/0/en/Latest-Research-Evaluating-VASCEPA-Icosapent-Ethyl-Mechanisms-of-Action-Presented-at-European-Atherosclerosis-Society-EAS-Congress-2020.html     OTOH: VASCEPA is the original product and proce$$,  not just a generic from small companies,   is it ok!?
                                    1
                                    • Sell Amarin , buy Teva
                                      1
                                      • REALLY Mr. Max. ? why you say this can you please explain to me ? why you basis so much in Teva even i have good experience in Teva i love Israeli people they are very smart and intelligent.
                                        0
                                    • "Hedge Funds Are Dumping Amarin Corporation plc (AMRN)"
                                      0
                                      • and they are buying TEVA 👍
                                        0
                                    • https://www.google.com/amp/s/finance.yahoo.com/amphtml/news/amarin-amrn-vascepa-international-opportunity-001638755.html
                                      1
                                      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.